PreciseDx is an augmented intelligence healthcare services provider delivering patient-specific insights through our AI-driven pathology tests and labs.
Location: United States, New York
Total raised: $20.7M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.08.2024 | Series B | $20.7M | - |
Mentions in press and media 11
| Date | Title | Description |
| 22.08.2024 | PreciseDx's $20.7 Million Boost: A New Dawn for AI in Cancer Diagnostics | In the world of oncology, every second counts. PreciseDx, a trailblazer in cancer diagnostics, has just secured a significant lifeline. The company raised $20.7 million in Series B funding, bringing its total funding to $31.5 million. This ... |
| 21.08.2024 | PreciseDx Raises $20.7M in Series B Funding | PreciseDx®, a NYC-based innovator in oncology diagnostics leveraging Artificial Intelligence, raised $20.7M in Series B funding. The round was led by Eventide Asset Management, with participation from Labcorp, Quest Diagnostics, and GenHenn... |
| 21.08.2024 | PreciseDx Secures $20.7 Million Series B to Advance AI-Powered Cancer Risk Assessments | Funding will support expanded commercialization efforts for PreciseBreast™ risk assessment NEW YORK, Aug. 21, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morp... |
| 21.08.2024 | PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments | What You Should Know: – PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, Ge... |
| 23.07.2024 | PreciseDx Announces Publication of Its Cost Impact Study, Payer Impact of PreciseBreast™(PDxBr) to Identify Breast Cancer Recurrence, in the Journal Of Medical Economics | PreciseBreast™ has the potential to deliver significant savings to payers and patients, while providing a more accurate measure of clinical risk; ultimately supporting treatment and management decisions for all patients with invasive breast... |
| 28.05.2024 | PreciseDx Announces Poster Presentation at The 2024 American Society of Clinical Oncology Annual Meeting | The poster presentation features findings from PreciseDx's collaboration with the Laboratory of Pathology, Dordrecht Albert Schweitzer Hospital in the Netherlands. NEW YORK, May 28, 2024 /PRNewswire/ -- PreciseDx®, a leading innovator in on... |
| 08.04.2024 | UCLA, PreciseDx to Develop AI-Powered Breast Cancer Recurrence Tool for Early Detection | What You Should Know: – PreciseDx®, a leader in AI-powered diagnostics for oncology, announces a crucial collaboration with UCLA’s Department of Pathology and Laboratory Medicine. – The research initiative focuses on evaluating PreciseDx’s ... |
| 21.01.2023 | PreciseDx Announces Publication in Breast Cancer Research; Validates Its AI-Enabled Platform that Predicts Early-Stage Breast Cancer Recurrence Better than Current Industry Standard | PreciseDx, a leading innovator in AI-powered, patient-specific disease analysis, announced its recent publication in Breast Cancer Research, demonstrating the ability of its digital AI platform to enrich breast cancer grading and improve ri... |
| 13.01.2022 | DexCare scoops up $50M and other digital health fundings | Photo: Getty Images/filadendron |
| 12.01.2022 | PreciseDx Raises $10.75 Million Series A Preferred from Healthcare Industry Leaders To Commercialize Cancer Risk Stratification Services To Support Better Patient Insights And Outcomes | Services Improve the Information Available to Oncologists and Pathologists in Determining Patient Risk Profiles and Treatment Diagnostic Industry Veteran Wayne Brinster Joins as CEO PreciseDx, the only Cancer Risk Stratification company to ... |
Show more